PT - JOURNAL ARTICLE AU - Takahashi, Shiho AU - Takarada, Tetsuhito AU - Ito, Kanako AU - Shikano, Mayumi AU - Sakurai, Shingou TI - Quality Culture and Knowledge Management in the Japanese Pharmaceutical Industry—A Cross-Sectional Study and Case Report AID - 10.5731/pdajpst.2022.012797 DP - 2023 Sep 01 TA - PDA Journal of Pharmaceutical Science and Technology PG - 350--375 VI - 77 IP - 5 4099 - http://journal.pda.org/content/77/5/350.short 4100 - http://journal.pda.org/content/77/5/350.full SO - PDA J Pharm Sci Technol2023 Sep 01; 77 AB - In the past few years, there have been several instances of illicit pharmaceutical manufacturing in Japan. Insufficient good manufacturing practice compliance and lack of quality culture in some pharmaceutical companies have been suggested as the underlying reasons for such cases. We aimed to focus on knowledge management and fostering of quality culture in pharmaceutical companies in Japan to understand their current situation and find a strategy for the availability of high-quality reliable pharmaceutical products. A wide-ranging questionnaire survey was conducted to understand the issues related to knowledge management and fostering of quality culture across pharmaceutical companies in Japan. A published investigation report on an illicit manufacturing case was closely examined by organizing the available facts using the diagram. Based on 395 responses to the questionnaire survey, we found that although pharmaceutical companies understand the importance of knowledge management and quality culture, issues exist in their operational methods. A total of 94% of the respondents agreed that they mentioned “knowledge management” as an enabler of the Pharmaceutical Quality System of ICH Q10, and 98% of the respondents accepted that insufficient fostering of quality culture leads to corporate risk. However, the survey revealed that many companies are struggling with this approach. Based on a report on an illicit manufacturing case, we analyzed the direct causes of misconduct and prepared a systematic summary that can be easily comprehended. Comparison of the illicit manufacturing case report with our questionnaire results suggests that many pharmaceutical companies do not regard the misconduct case as a situation that could occur in their company. With the revision of the Pharmaceuticals and Medical Devices Act and good manufacturing practice Ministerial Ordinance, we advocate the need for all employees of pharmaceutical companies to reconsider the priorities of their companies from the patient perspective.